Clinical Prior Authorization Update for Topical Immunomodulators Scheduled for August 13, 2020

Clinical Prior Authorization Update for Topical Immunomodulators Scheduled for August 13, 2020

VDP routinely updates existing clinical prior authorization criteria to reflect recent FDA-approved indications or safety information from the product package insert. FirstCare will revise the Eucrisa (crisaborole) criteria within the Topical Immunomodulators clinical prior authorization on August 13, 2020: 

• Previously, Eucrisa was indicated for children 2 years of age and older. Recently, Eucrisa had an age extension for the treatment of mild to moderate topical dermatitis for children age 3 months and older. 
• Revised criteria will acknowledge this age change to allow children less than 2 years of age to receive Eucrisa without the requirement for a trial of a topical steroid